Evaluating the cross-reactivity of a stool methylated syndecan-2 (meSDC2) test in colorectal cancer detection
The stool me<i>SDC2</i> test demonstrated a high positivity rate in CRC but showed low positivity rates in other cancers, except in biliary tract cancer. This indicates that the stool me<i>SDC2</i> test has a high specificity for CRC, as the results are minimally influenced by other cancer types.
Authors
- Sang Hyoung Park (ORCID: https://orcid.org/0000-0002-5366-5749)
- Sung Wook Hwang (ORCID: https://orcid.org/0000-0001-7816-2307)
- Byong Duk Ye (ORCID: https://orcid.org/0000-0001-6647-6325)
- Seung-Jae Myung
- Dong‐Hoon Yang (ORCID: https://orcid.org/0000-0001-7756-2704)
- Sungwhan An
- Seung Wook Hong
- Suk-Kyun Yang
- Tae Jeong Oh
- Jeong‐Sik Byeon
Institutions
- Ulsan College (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
Publication Details
- Journal
- Journal of Gastrointestinal Oncology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/jgo-2025-270
- Citations
- 1
- Primary Topic
- Colorectal Cancer Screening and Detection
- Type
- article
- Field-Weighted Citation Impact
- 1.05